Noise-Texture_edited.jpg
germany flag.png

Sydney, Australia

Psylo

Exact health.png

Mental disorders account for one of the largest and fastest growing categories of the burden of disease worldwide. Mental ill-health has devastating effect on individuals, families and communities, and weighs heavily on societies and economies - the economic burden of mental ill-health can rise to up to 4% of GDP, and those with mental illness have poorer educational and work outcomes than those in good mental health.

Psylo is building a proprietary platform for developing psychedelic medicines to redefine how we treat mental illness. The Psylo team is uniquely positioned to transform mental health treatment with the application of psychedelics. Collectively, they bring years of experience researching cannabinoids and building deep biotech companies. And, like all great company-builders, the founding team has assembled a supporting tribe of industry-leading biotech investors and psychedelic experts.

Secondary page half circle.png

Founders

Joshua Ismin

CEO

Sam Banister

CSO